These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 18624972)
1. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. Meriggiola MC; Armillotta F; Costantino A; Altieri P; Saad F; Kalhorn T; Perrone AM; Ghi T; Pelusi C; Pelusi G J Sex Med; 2008 Oct; 5(10):2442-53. PubMed ID: 18624972 [TBL] [Abstract][Full Text] [Related]
2. Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. Juang PS; Peng S; Allehmazedeh K; Shah A; Coviello AD; Herbst KL J Sex Med; 2014 Feb; 11(2):563-73. PubMed ID: 24344872 [TBL] [Abstract][Full Text] [Related]
3. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C J Androl; 2006; 27(6):853-67. PubMed ID: 16837736 [TBL] [Abstract][Full Text] [Related]
5. Novel treatment of short stature with aromatase inhibitors. Dunkel L; Wickman S J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):345-56. PubMed ID: 14623531 [TBL] [Abstract][Full Text] [Related]
6. The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. Bunck MC; Toorians AW; Lips P; Gooren LJ Eur J Endocrinol; 2006 Apr; 154(4):569-75. PubMed ID: 16556720 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. Wang C; Harnett M; Dobs AS; Swerdloff RS J Androl; 2010; 31(5):457-65. PubMed ID: 20133964 [TBL] [Abstract][Full Text] [Related]
9. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate. Yassin AA; Saad F Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216 [TBL] [Abstract][Full Text] [Related]
10. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. de Boer H; Verschoor L; Ruinemans-Koerts J; Jansen M Diabetes Obes Metab; 2005 May; 7(3):211-5. PubMed ID: 15811136 [TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641 [TBL] [Abstract][Full Text] [Related]
12. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. Amory JK; Bremner WJ J Clin Endocrinol Metab; 2005 May; 90(5):2610-7. PubMed ID: 15713724 [TBL] [Abstract][Full Text] [Related]
13. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. von Eckardstein S; Nieschlag E J Androl; 2002; 23(3):419-25. PubMed ID: 12002444 [TBL] [Abstract][Full Text] [Related]
14. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. Neely EK; Kumar RB; Payne SL; Ranadive SA; Suchet DI J Clin Endocrinol Metab; 2014 Nov; 99(11):4086-93. PubMed ID: 25137428 [TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ J Androl; 1998; 19(6):761-8. PubMed ID: 9876028 [TBL] [Abstract][Full Text] [Related]
16. A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition, and Metabolic Profile in Transmen. Gava G; Armillotta F; Pillastrini P; Giagio S; Alvisi S; Mancini I; Morselli PG; Seracchioli R; Meriggiola MC J Sex Med; 2021 Mar; 18(3):646-655. PubMed ID: 33531255 [TBL] [Abstract][Full Text] [Related]
17. Effects of three different testosterone formulations in female-to-male transsexual persons. Pelusi C; Costantino A; Martelli V; Lambertini M; Bazzocchi A; Ponti F; Battista G; Venturoli S; Meriggiola MC J Sex Med; 2014 Dec; 11(12):3002-11. PubMed ID: 25250780 [TBL] [Abstract][Full Text] [Related]
18. [The effect of administering testosterone undecanoate on hormone levels in female transsexuals]. Stárka L; Hampl R; Heresová J; Sípová I Bratisl Lek Listy; 1986 Feb; 85(2):202-8. PubMed ID: 3082467 [No Abstract] [Full Text] [Related]
19. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493 [TBL] [Abstract][Full Text] [Related]
20. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Hero M; Wickman S; Dunkel L Clin Endocrinol (Oxf); 2006 May; 64(5):510-3. PubMed ID: 16649968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]